Lite Strategy, Inc.是一家临床阶段的制药公司,致力于开发新型和差异化的癌症疗法。该公司通过收购有前途的癌症药物来建立管道,并通过临床开发、战略合作伙伴关系以及外包许可或商业化(视情况而定)在项目中创造价值。他们的候选药物管线包括voruciclib,一种口服细胞周期蛋白依赖性激酶9(CDK9)抑制剂和zandelisib,一种口服、每日一次、选择性PI3K δ抑制剂,这是一种临床前候选药物。
董事
名称
职位
Justin J. File
Chief Executive Officer,Chief Financial Officer,Director and Secretary
Frederick W. Driscoll
Independent Director and Chair of the Board
James Flynn
Independent Director
Nicholas R. Glover
Independent Director
Charles B. Lee
Director
Joshua Riezman
Director
股东
名称
职位
Justin J. File
Chief Executive Officer,Chief Financial Officer,Director and Secretary